HOLLYWOOD, FL--(Marketwire - May 27, 2009) - bioRASI, a full service, global Contract
Research Organization (CRO), announced today that they will be
participating in the MAGI 2009 Clinical Research Conference on May 31st -
June 3rd. Dr. Boris Reznik, Chairman of bioRASI, will be a keynote speaker
at the event's symposium titled, "Lessons Learned, Study Post Mortems."
Leading the Symposium, Dr. Reznik will be discussing the issues of
improving Clinical Research Processes through applying Deming's "Continues
Improvement Process" (CIP).
"Too often, 'Lessons Learned' is reduced to trying to derive value from
anecdotal review of the issues after the clinical trials are completed,"
Dr. Boris Reznik said. "At bioRASI, in order to consistently increase the
quality of our work, we have been applying a method developed by the
legendary W. Edwards Deming: 'Continues Improvement Process.' We not only
believe that our approach produces significantly improved results, but we
actually can measure them. The successful implementation of CIP at bioRASI
was based upon making CIP a part of bioRASI's standard operating
infrastructure: BPI 2008."
Through its Innovative and Generics divisions, bioRASI leverages its
in-depth knowledge and global resources to provide a full range of services
to its sponsors, including program management, regulatory strategy design
and implementation, clinical development, analytical lab services, Part 11
compliant data management, data analysis and report writing.
bioRASI has leveraged its unique global access to strong PIs and special
patient populations to optimize translational clinical development
programs. Additionally, utilizing bioRASI's Phase I clinics and
bioanalytical laboratories, bioRASI has a rich history of completing
difficult to recruit and difficult to perform PK, BE and BA studies.
bioRASI is a Full Service Global CRO that collaborates with the leading
biotech and pharmaceutical companies in the clinical development of novel
and generic therapeutics. Specializing in Innovative, ANDA and 505(b)(2)
NDA programs, bioRASI facilitates obtaining FDA approvals by delivering
high quality regulatory and clinical strategies, solutions and services,
while saving their clients critical time. bioRASI services include program
management, regulatory, clinical, data management and analysis, compliance
and audit. bioRASI leverages its access to world renowned researchers and
facilities in the U.S., Europe and Asia, to achieve unparalleled
scientific, clinical and business results at significantly lower costs.
bioRASI is headquartered in Hollywood, FL and has regional offices, labs,
and clinics across the globe.